Grace Therapeutics GRCE Income Statement (2017-2026)

NASDAQ GRCE
$2.14 -0.06 (-2.73%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Feb2017 Mar2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
5.46M7.38M6.14M7.42M7.44M7.44M7.44M7.44M7.55M9.40M9.40M10.14M10.14M10.14M13.72M13.83M14.13M15.47M16.02M16.27M
Revenue & cost
Revenue (Quarter)
Gross Profit (Quarter)
Operating items
Research & Development (Quarter)
0.58M2.18M2.33M2.59M0.14M2.45M1.64M1.09M0.46M1.44M1.69M2.71M2.98M2.19M1.63M0.95M0.57M0.46M0.42M0.70M
Wages, Salaries and Other (Quarter)
0.60M0.73M0.62M0.61M0.99M0.76M0.87M1.55M0.90M
Selling, General & Administrative (Quarter)
2.96M1.81M1.82M1.92M1.68M1.59M2.43M1.87M1.63M1.60M1.58M2.25M1.85M1.51M1.55M2.13M1.96M1.99M2.59M1.69M
Restructuring Costs (Quarter)
1.49M
Operating Expenses (Quarter)
3.54M3.99M4.15M4.51M1.82M4.04M4.07M4.45M2.09M3.04M3.26M4.96M4.83M3.70M3.18M3.09M2.53M2.45M3.01M2.38M
Operating Income (Quarter)
-3.57M-4.47M-4.40M-4.73M-5.11M-4.25M-38.07M-4.45M-2.09M-3.04M-3.26M-4.96M-4.83M-3.70M-3.18M-3.09M-2.53M-2.45M-3.01M-15.92M
EBIT (Quarter)
-3.57M-4.47M-4.40M-4.73M-5.11M-4.25M-38.07M-4.45M-2.09M-3.04M-3.26M-4.96M-4.83M-3.70M-3.18M-3.09M-2.53M-2.45M-3.01M-15.92M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.04M0.03M0.04M0.07M0.11M0.13M0.21M0.32M0.25M0.23M0.17M0.14M0.17M0.20M0.17M0.17M0.14M0.14M
Other Non Operating Income (Quarter)
1.10M-0.17M-0.25M-0.08M-0.01M-0.01M-1.24M0.01M-0.01M0.00M-0.01M-0.01M0.01M-0.02M0.01M0.01M-0.01M0.00M-0.01M-0.01M
Non Operating Income (Quarter)
4.55M0.70M-0.15M-0.04M0.02M0.08M0.12M0.14M-1.63M0.44M-0.79M1.62M0.55M-1.06M2.80M-0.27M1.59M0.13M0.13M0.13M
Net income details
EBT (Quarter)
0.98M-3.78M-4.55M-4.77M-5.08M-4.16M-37.96M-4.31M-3.72M-2.60M-4.05M-3.34M-4.28M-4.76M-0.38M-3.36M-0.94M-2.31M-2.88M-15.79M
Tax Provisions (Quarter)
-2.77M-0.24M-0.15M-0.27M0.67M-0.29M-0.45M-0.21M0.60M-0.72M-0.85M-0.60M-0.50M-1.70M
Profit After Tax (Quarter)
0.98M-3.78M-7.82M-4.52M-4.93M-3.89M-29.09M-4.02M-3.27M-2.39M-3.17M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.31M-1.18M-15.79M
Income from Continuing Operations (Quarter)
0.98M-3.78M-1.78M-4.52M-4.93M-3.89M-38.63M-4.02M-3.27M-2.39M-4.66M-2.62M-3.43M-4.16M0.12M-3.36M-0.94M-2.31M-1.18M-15.79M
Consolidated Net Income (Quarter)
0.98M-3.78M-1.78M-4.52M-4.93M-3.89M-38.63M-4.02M-3.27M-2.39M-4.66M-2.62M-3.43M-4.16M0.12M-3.36M-0.94M-2.31M-1.18M-15.79M
Income towards Parent Company (Quarter)
0.98M-3.78M-1.78M-4.52M-4.93M-3.89M-38.63M-4.02M-3.27M-2.39M-4.66M-2.62M-3.43M-4.16M0.12M-3.36M-0.94M-2.31M-1.18M-15.79M
Net Income towards Common Stockholders (Quarter)
0.98M-3.78M-1.78M-4.52M-4.93M-3.89M-38.63M-4.02M-3.27M-2.39M-4.66M-2.62M-3.43M-4.16M0.12M-3.36M-0.94M-2.31M-1.18M-15.79M
Additional items
EPS (Basic) (Quarter)
0.18-0.51-0.29-0.61-0.66-0.52-5.20-0.54-0.43-0.21-0.49-0.24-0.30-0.360.01-0.21-0.06-0.14-0.07-0.91
EPS (Diluted) (Quarter)
0.18-0.51-0.29-0.61-0.66-0.52-5.20-0.54-0.43-0.21-0.49-0.24-0.30-0.360.01-0.21-0.06-0.14-0.07-0.91
Shares Outstanding (Quarter)
5.46M7.38M6.14M7.39M7.43M7.44M7.44M7.44M7.55M11.51M9.53M10.93M11.51M11.51M12.09M15.92M15.92M16.93M16.51M17.27M
Shares Outstanding (Diluted) (Quarter)
5.46M7.38M6.14M7.39M7.43M7.44M7.44M7.44M7.55M11.51M9.53M10.93M11.51M11.51M12.09M15.92M15.92M16.93M16.51M17.27M
EBITDA (Quarter)
-3.57M-4.47M-4.40M-4.73M-5.11M-4.25M-38.07M-4.45M-2.09M-3.04M-3.26M-4.96M-4.83M-3.70M-3.18M-3.09M-2.53M-2.45M-3.01M-15.92M
Interest Expenses (Quarter)
42.40M0.09M0.08M0.00M0.02M0.06M0.29M0.86M0.02M0.59M0.60M1.16M2.56M0.09M
Tax Rate (Quarter)
60.945.083.056.58-1.776.7011.998.00-14.8521.6719.8912.71130.8959.07